Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

Just Released: "Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018"


Print article Print article
2014-03-21 18:53:19 - Fast Market Research recommends "Investigation Report on China Valsartan Hydrochlorothiazide Market, 2009-2018" from CRI, now available

Description
According to WHO, one-third of the world's adults have hypertension. The global market value of antihypertensive drugs is tens of billion dollars.

Due to the long history of antihypertensive drugs, most hypertensive patients need 2 or more kinds of antihypertensive drugs to reduce the blood pressure to a normal level. There are more than 20 compound preparations of sartan drugs in global market. The first category is the compound preparation of sartan and diuretic hydrochlorothiazide. Because the compound of sartan drugs and diuretic has better effect than other medication compounds, most sartan and hydrochlorothiazide compound preparations are approved by FDA, including the compound preparation of diuretic chlorthalidone and azilsartan. The second category is the compound preparation of sartan and calcium antagonist.

The third category is the direct renin inhibitor and sartan compound preparation. The fourth one is triplex compound preparation. Novartis developed valsartan compound preparation after valsartan was launched. In October 1997, the compound preparation of valsartan hydrochlorothiazide was successfully developed by Novartis and approved by FDA with the trade name "CoDiovan". Unlike valsartan, valsartan hydrochlorothiazide tablet can only treat hypertension instead of congestive heart failure and myocardial infarction.

Full Report Details at
- www.fastmr.com/prod/782777_investigation_report_on_china_valsart ..

Statistics shows that the number of hypertensive patients in China is higher than 260 million, which may even be more than 300 million. According to CRI, market value of hypertensive drugs in China exceeds CNY 40 billion every year. The CAGR of sales revenue of valsartan hydrochlorothiazide in Chinese sample hospitals surpassed 100% from 2007 to 2012. Based on the sales revenue, Novartis takes more than 80% of the valsartan hydrochlorothiazide market in China while the other market is seized by Chinese enterprises such as Jiangsu Wangao Pharmaceutical Co., Ltd.

It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard and changes of lifestyle. As Chinese people's incomes increase, the affordability of antihypertensive drugs increases. As a result, market size of Valsartan Hydrochlorothiazide in China will keep increasing in the next few years.

Through this report, the readers can acquire the following information:

* Market Share of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market
* Sales Value of Valsartan Hydrochlorothiazide in China Hospital Market
* Major Valsartan Hydrochlorothiazide Manufacturers in China
* Prospect of China Valsartan Hydrochlorothiazide Market

The following enterprises and people are recommended to purchase this report:

* Antihypertensive APIs and Finished Product Manufacturers
* Investors /Research Agencies Focusing on China Antihypertensive Drug Market

Partial Table of Contents:

Table of Contents
1 Relevant Concepts of Valsartan Hydrochlorothiazide
1.1 Development Process and Indication
1.2 Sales Status on the Global Market

2 Market Overview of Valsartan Hydrochlorothiazide in China, 2009-2013
2.1 Patent Status
2.2 Major Manufacturers
2.3 Market Size

3 Investigation on Sales Value of Valsartan Hydrochlorothiazide in China, 2009-2013
3.1 Total Sales Value
3.2 Sales Value by Region

4 Investigation on Market Share of Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2013
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Investigation on Market Size of Valsartan Hydrochlorothiazide by Dosage Form in China, 2009-2013
5.1 Market Size by Sales Value
5.2 Market Size by Sales Volume

6 Reference Price of Valsartan Hydrochlorothiazide Produced by Different Enterprises in China Hospital Market, 2014
6.1 Novartis
6.2 Jiangsu Wangao Pharmaceutical Co., Ltd.
6.3 China Resources Saike Pharmaceutical Co., Ltd.
6.4 Lunan Better Pharmaceutical Co., Ltd.
6.5 Cisen Pharmaceutical Co., Ltd.
6.6 Conquer Pharmaceutical Co., Ltd.
6.7 Bailu Pharmaceutical Co., Ltd.
6.8 Changzhou Siyao Pharmaceutical Co., Ltd.

7 Analysis on Major Valsartan Hydrochlorothiazide Manufacturers in China, 2009-2014
7.1 Novartis
7.2 Jiangsu Wangao Pharmaceutical Co., Ltd.
7.3 China Resources Saike Pharmaceutical Co., Ltd.
7.4 Lunan Better Pharmaceutical Co., Ltd.
7.5 Cisen Pharmaceutical Co., Ltd.

8 Market Overview of Valsartan Hydrochlorothiazide in China, 2014-2018
8.1 Forecast on Incidence of Hypertension
8.2 Forecast on Market Size
8.3 Forecast on Competition Pattern

Selected Charts
Chart Valsartan Hydrochlorothiazide Products Approved to Market in China by 2014
Chart Sales Value of Valsartan Hydrochlorothiazide in Global Market, 2009-2013
Chart Sales Value of Valsartan Hydrochlorothiazide in China Hospital Market, 2009-2013
Chart Market Share of Valsartan Hydrochlorothiazide Enterprises by Sales Value in China, 2009-2013
Chart Price of Valsartan Hydrochlorothiazide Produced by Novartis in China Hospital Market, 2014
Chart Price of Valsartan Hydrochlorothiazide Produced by Jiangsu Wangao Pharmaceutical Co., Ltd. in China Hospital Market, 2014

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=782777&dt=t

About CRI

CRI is a research and consulting company located in Shanghai, China, focusing on various industries and markets. It regularly produces a variety of market research reports, industry analytical reports publications covering 11 industries. It also provides customized industry research services for initial public offerings, corporate mergers and acquisitions, business development, market launch and financing. View more research from CRI at www.fastmr.com/catalog/publishers.aspx?pubid=1045

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com